STSA-1005 / Staidson Biopharma - LARVOL DELTA

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Terminated | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Trial completion date: Aug 2024 ➔ Mar 2024 | Recruiting ➔ Terminated; Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.

Trial completion date • Trial termination

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Trial completion date: Dec 2023 ➔ Aug 2024 | Trial primary completion date: Sep 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • CSF2 • CXCL8 • IL10 • IL2 • IL6

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd

New P1 trial • CSF2 • CXCL8 • IL10 • IL2 • IL6

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Staidson Biopharma Inc. | Recruiting ➔ Completed

Trial completion • CSF2